A randomized phase II/III study of 'novel therapeutics' versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612

被引：6
|
作者：
Assouline, Sarit [1 ]
Michaelis, Laura C. [2 ]
Othus, Megan [3 ]
Hay, Annette E. [4 ]
Walter, Roland B. [5 ]
Jacoby, Meagan A. [6 ]
Schroeder, Mark A. [6 ]
Uy, Geoffrey L. [6 ]
Law, Lisa Y. [7 ]
Cheema, Faisal [8 ]
Sweet, Kendra L. [9 ]
Asch, Adam S. [10 ]
Liu, Jijun [11 ]
Moseley, Anna B. [2 ]
Maher, Tracy [12 ]
Kingsbury, Laura L. [12 ]
Fang, Min [5 ]
Radich, Jerald [5 ]
Little, Richard F. [13 ]
Erba, Harry P. [14 ]
机构：
[1] McGill Univ, Jewish Gen Hosp, Montreal, PQ H3T 1E2, Canada
[2] Med Coll Wisconsin, Milwaukee, WI USA
[3] SWOG Stat & Data Management Ctr, Seattle, WA USA
[4] Queens Univ, Kingston, ON, Canada
[5] Fred Hutchinson Canc Res Ctr, Seattle, WA USA
[6] Washington Univ, Sch Med, St Louis, MO USA
[7] Kaiser Permanente NCAL, Roseville, CA USA
[8] Kaiser Permanente, Santa Clara, CA USA
[9] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[10] Univ Oklahoma HSC, Oklahoma City, OK USA
[11] Illinois Canc Care Heartland NCORP, Peoria, IL USA
[12] SWOG Data Operat Ctr, Canc Res & Biostat, Seattle, WA USA
[13] Natl Canc Inst, Canc Therapy & Evaluat Program CTEP, Bethesda, MD USA
[14] Duke Univ, Duke Canc Inst, Med Ctr, Durham, NC USA
来源：
LEUKEMIA & LYMPHOMA | 2023年 / 64卷 / 02期
基金：
美国国家卫生研究院;
关键词：
CONVENTIONAL-CARE-REGIMENS; THERAPY;
D O I：
10.1080/10428194.2022.2148212
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：473 / 477
页数：5
相关论文
共 50 条
  • [31] Phase I/II Study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in Patients (pts) with Newly Diagnosed (ND) Older/Unfit or High-Risk Acute Myeloid Leukemia (AML) and Relapsed/Refractory (R/R) AML
    Daver, Naval
    Senapati, Jayastu
    Maiti, Abhishek
    Loghavi, Sanam
    Kadia, Tapan M.
    DiNardo, Courtney D.
    Pemmaraju, Naveen
    Jabbour, Elias
    Montalban-Bravo, Guillermo
    Tang, Guilin
    Sasaki, Koji
    Borthakur, Gautam
    Yilmaz, Musa
    Alvarez, Joie
    Pierce, Sherry A.
    Gonzalez, Graciela M. Nogueras
    Ning, Jing
    Issa, Ghayas C.
    Andreeff, Michael
    Abbas, Hussein A.
    Ravandi, Farhad
    Garcia-Manero, Guillermo
    Kantarjian, Hagop
    BLOOD, 2022, 140
  • [32] A Randomized Phase II Study of Tosedostat in Combination with Either Cytarabine or Decitabine in Newly Diagnosed Older Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
    Mawad, Raya
    Becker, Pamela S.
    Hendrie, Paul C.
    Scott, Bart L.
    Wood, Brent L.
    Dean, Carol
    Sandhu, Vicky
    Deeg, H. Joachim
    Walter, Roland B.
    Wang, Lixia
    Singer, Jack
    Estey, Elihu H.
    Pagel, John
    BLOOD, 2014, 124 (21)
  • [33] Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117
    Sekeres, Mikkael A.
    Othus, Megan
    List, Alan F.
    Odenike, Olatoyosi
    Stone, Richard M.
    Gore, Steven D.
    Litzow, Mark R.
    Buckstein, Rena
    Fang, Min
    Roulston, Diane
    Bloomfield, Clara D.
    Moseley, Anna
    Nazha, Aziz
    Zhang, Yanming
    Velasco, Mario R.
    Gaur, Rakesh
    Atallah, Ehab
    Attar, Eyal C.
    Cook, Elina K.
    Cull, Alyssa H.
    Rauh, Michael J.
    Appelbaum, Frederick R.
    Erba, Harry P.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (24) : 2745 - +
  • [34] Results of a Phase 2, Open-Label Study of Idarubicin (I), Cytarabine (A) and Nivolumab (Nivo) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)
    Assi, Rita
    Kantarjian, Hagop M.
    Daver, Naval G.
    Garcia-Manero, Guillermo
    Benton, Christopher B.
    Thompson, Philip A.
    Borthakur, Gautam
    Kadia, Tapan M.
    Alvarado, Yesid
    Jabbour, Elias J.
    Konopleva, Marina Y.
    Takahashi, Koichi
    Kornblau, Steven M.
    DiNardo, Courtney D.
    Estrov, Zeev E.
    Flores, Wilmer
    Basu, Sreyashi
    Allison, James P.
    Sharma, Padmanee
    Pierce, Sherry A.
    Pike, Allison
    Cortes, Jorge E.
    Ravandi, Farhad
    BLOOD, 2018, 132
  • [35] Phase 3 study of first line pevonedistat (PEV) plus azacitidine (AZA) versus single-agent AZA in patients with higher-risk myelodysplastic syndromes (HR MDS), chronic myelomonocytic leukemia (CMML) or low-blast acute myelogenous leukemia (AML).
    Sekeres, Mikkael A.
    Fram, Robert J.
    Hua, Zhaowei
    Ades, Lionel
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [36] Pevonedistat (PEV) plus Azacitidine (AZA) Versus AZA Alone As First-Line Treatment for Patients with Higher-Risk Myelodysplastic Syndromes (MDS)/Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) with 2030% Marrow Blasts: The Randomized Phase 3 PANTHER Trial (NCT03268954)
    Sekeres, Mikkael A.
    Girshova, Larisa
    Doroni, Vadim A.
    Diez-Campelo, Maria
    Valcarcel, David
    Kambhampati, Suman
    Viniou, Nora-Athina
    Woszczyk, Dariusz
    De Paz Arias, Raquel
    Symeonidis, Argiris
    Anagnostopoulos, Achilles
    Munhoz, Eduardo Ciliao
    Platzbecker, Uwe
    Santini, Valeria
    Fram, Robert J.
    Yuan, Ying
    Faller, Douglas V.
    Ades, Lionel
    BLOOD, 2021, 138
  • [37] Phase I/II study of vosaroxin and decitabine in older patients (pts) with acute myeloid leukemia (AML) and high risk myelodysplastic syndrome (MDS)
    Daver, Naval
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    Pemmaraju, Naveen
    Kadia, Tapan
    DiNardo, Courtney
    Jain, Nitin
    Borthakur, Gautum
    Cortes, Jorge
    Adam, Craig
    Ravandi, Farhad
    CANCER RESEARCH, 2014, 74 (19)
  • [38] Phase II Study of 5-Azacitidine and Vorinostat In Patients (pts) with Newly Diagnosed Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia (AML) Not Eligible for Clinical Trials Because Poor Performance or Presence of Other comorbidities
    Garcia-Manero, Guillermo
    Estey, Elihu H.
    Jabbour, Elias
    Kadia, Tapan
    Estrov, Zeev
    Cortes, Jorge
    Boone, Patricia Ann
    Kantarjian, Hagop M.
    BLOOD, 2010, 116 (21) : 266 - 266
  • [39] Final Report of a Phase II Study of 5-Azacitidine and Vorinostat in Patients (pts) with Newly Diagnosed Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia (AML) Not Eligible for Clinical Trials Because Poor Performance and Presence of Other Comorbidities
    Garcia-Manero, Guillermo
    Estey, Elihu H.
    Jabbour, Elias
    Borthakur, Gautam
    Kadia, Tapan
    Naqvi, Kiran
    Levine, Ross L.
    Estrov, Zeev
    Quintas-Cardama, Alfonso
    Konopleva, Marina
    Faderl, Stefan
    Tanaka, Maria
    Yang, Hui
    Ravandi, Farhad
    Wierda, William G.
    Cortes, Jorge E.
    Boone, Patricia Ann
    Kantarjian, Hagop M.
    BLOOD, 2011, 118 (21) : 279 - 279
  • [40] CASCADE: A phase 3, randomized, double-blind study of vadastuximab talirine (33A) versus placebo in combination with azacitidine or decitabine in the treatment of older patients with newly diagnosed acute myeloid leukemia (AML).
    Wang, Eunice S.
    Ades, Lionel
    Fathi, Amir Tahmasb
    Kreuzer, Karl A.
    O'Meara, Megan Marie
    Liang, Shang-Ying
    Ravandi, Farhad
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345